The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Systemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice
Open accessAbstract
Alpha‐synuclein (α‐Syn) aggregates are the main component of Lewy bodies, which are the characteristic pathological feature in Parkinson's disease (PD) brain. Evidence that α‐Syn aggregation can be propagated between neurones has led to the suggestion that this mechanism is responsible for the stepwise progression of PD pathology. Decreasing α‐Syn expression is predicted to attenuate this process and is thus an attractive approach to delay or halt PD progression. We have used α‐Syn small interfering RNA (siRNA) to reduce total and aggregated α‐Syn levels in mouse brains. To achieve widespread delivery of siRNAs to the brain we have peripherally injected modified exosomes expressing Ravies virus glycoprotein loaded with siRNA. Normal mice were analyzed 3 or 7 days after injection. To evaluate whether this approach can decrease α‐Syn aggregates, we repeated the treatment using transgenic mice expressing the human phosphorylation‐mimic S129D α‐Syn, which exhibits aggregation. In normal mice we detected significantly reduced α‐Syn messenger RNA (mRNA) and protein levels throughout the brain 3 and 7 days after treatment with RVG‐exosomes loaded with siRNA to α‐Syn. In S129D α‐Syn transgenic mice we found a decreased α‐Syn mRNA and protein levels throughout the brain 7 days after injection. This resulted in significant reductions in intraneuronal protein aggregates, including in dopaminergic neurones of the substantia nigra. This study highlights the therapeutic potential of RVG‐exosome delivery of siRNA to delay and reverse brain α‐Syn pathological conditions. © 2014 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Self-citationα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,416
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
“RVG-modified exosomeswith siRNA targeting a-synuclein reduced aggregate formation in the brains of S129D a-synuclein mice and improved brain pathology (143).”
Progress in Exosome Isolation Techniques
Li, P., Kaslan, M., Lee, S. H., Yao, J., & Gao, Z. (2017) · Theranostics · doi:10.7150/thno.18133 · Cited by 1,948
The biology and function of exosomes in cancer
Kalluri, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81135 · Cited by 1,849
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Extracellular vesicles as drug delivery systems: Why and how?
Elsharkasy, O. M., Nordin, J. Z., Hagey, D. W., de Jong, O. G., Schiffelers, R. M., Andaloussi, S. E., & Vader, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.004 · Cited by 1,197
Self-citationStrategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Self-citationExosomes: Therapy delivery tools and biomarkers of diseases
Barile, L., & Vassalli, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.020 · Cited by 1,038
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Generation and testing of clinical-grade exosomes for pancreatic cancer
Mendt, M., Kamerkar, S., Sugimoto, H., McAndrews, K. M., Wu, C.-C., Gagea, M., Yang, S., Blanko, E. V. R., Peng, Q., Ma, X., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99263 · Cited by 792
Engineering hybrid exosomes by membrane fusion with liposomes
Sato, Y. T., Umezaki, K., Sawada, S., Mukai, S.-A., Sasaki, Y., Harada, N., Shiku, H., & Akiyoshi, K. (2016) · Scientific Reports · doi:10.1038/srep21933 · Cited by 744
The blood-brain barrier: Physiology and strategies for drug delivery
Pandit, R., Chen, L., & Götz, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.009 · Cited by 651
Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics
Armstrong, J. P. K., Holme, M. N., & Stevens, M. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07607 · Cited by 602
Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1748758 · Cited by 592
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Mehra, S., Sahay, S., & Maji, S. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.03.001 · Cited by 499
Salunkhe, S., Dheeraj, Basak, M., Chitkara, D., & Mittal, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.042 · Cited by 497
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
Didiot, M.-C., Hall, L. M., Coles, A. H., Haraszti, R. A., Godinho, B. M., Chase, K., Sapp, E., Ly, S., Alterman, J. F., Hassler, M. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.126 · Cited by 483
Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Extracellular vesicles in neurodegenerative disease — pathogenesis to biomarkers
Thompson, A. G., Gray, E., Heman-Ackah, S. M., Mäger, I., Talbot, K., Andaloussi, S. E., Wood, M. J., & Turner, M. R. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.68 · Cited by 431
Self-citationKooijmans, S. A. A., Aleza, C. G., Roffler, S. R., van Solinge, W. W., Vader, P., & Schiffelers, R. M. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31053 · Cited by 426
Wang, X., Chen, Y., Zhao, Z., Meng, Q., Yu, Y., Sun, J., Yang, Z., Chen, Y., Li, J., Ma, T., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008737 · Cited by 422
Extracellular vesicles: novel promising delivery systems for therapy of brain diseases.
Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., & Pereira de Almeida, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.001 · Cited by 418
Gupta, D., Zickler, A. M., & El Andaloussi, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113961 · Cited by 418
Self-citationExosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
Ferguson, S. W., & Nguyen, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.037 · Cited by 416
Lamichhane, T. N., Raiker, R. S., & Jay, S. M. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00364 · Cited by 410
Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm
Yin, K., Wang, S., & Zhao, R. C. (2019) · Biomarker Research · doi:10.1186/s40364-019-0159-x · Cited by 380
Gurunathan, S., Kang, M.-H., & Kim, J.-H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s291956 · Cited by 379
Morishita, M., Takahashi, Y., Matsumoto, A., Nishikawa, M., & Takakura, Y. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.031 · Cited by 369
Bellavia, D., Raimondo, S., Calabrese, G., Forte, S., Cristaldi, M., Patinella, A., Memeo, L., Manno, M., Raccosta, S., Diana, P., et al. (2017) · Theranostics · doi:10.7150/thno.17092 · Cited by 368
Extracellular vesicles: A bright star of nanomedicine
Wu, P., Zhang, B., Ocansey, D. K. W., Xu, W., & Qian, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120467 · Cited by 368
Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders
Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., Ali, M., Li, J., & Li, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.23247 · Cited by 351
Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication
Lamichhane, T. N., Jeyaram, A., Patel, D. B., Parajuli, B., Livingston, N. K., Arumugasaamy, N., Schardt, J. S., & Jay, S. M. (2016) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-016-0457-4 · Cited by 347
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
RNA interference-based therapy and its delivery systems
Chen, X., Mangala, L. S., Rodriguez-Aguayo, C., Kong, X., Lopez-Berestein, G., & Sood, A. K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9717-6 · Cited by 329
Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity
Cheng, Q., Shi, X., Han, M., Smbatyan, G., Lenz, H.-J., & Zhang, Y. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10047 · Cited by 285
Bjørge, I. M., Kim, S. Y., Mano, J. F., Kalionis, B., & Chrzanowski, W. (2018) · Biomaterials Science · doi:10.1039/c7bm00479f · Cited by 275
Strategic design of extracellular vesicle drug delivery systems
Armstrong, J. P. K., & Stevens, M. M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.017 · Cited by 257
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration
Azam, S., Haque, M. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683459 · Cited by 255
Pham, T. C., Jayasinghe, M. K., Pham, T. T., Yang, Y., Wei, L., Usman, W. M., Chen, H., Pirisinu, M., Gong, J., Kim, S., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12057 · Cited by 250
Nanotechnology-based strategies for siRNA brain delivery for disease therapy
Zheng, M., Tao, W., Zou, Y., Farokhzad, O. C., & Shi, B. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.01.006 · Cited by 210
Lai, N., Wu, D., Liang, T., Pan, P., Yuan, G., Li, X., Li, H., Shen, H., Wang, Z., & Chen, G. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01745-0 · Cited by 205
Yang, T., Fogarty, B., LaForge, B., Aziz, S., Pham, T., Lai, L., & Bai, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0015-y · Cited by 204
New windows into the brain: Central nervous system-derived extracellular vesicles in blood
Shi, M., Sheng, L., Stewart, T., Zabetian, C. P., & Zhang, J. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.01.005 · Cited by 181
Extracellular Vesicles in Blood: Sources, Effects, and Applications
Alberro, A., Iparraguirre, L., Fernandes, A., & Otaegui, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158163 · Cited by 170
Extracellular Vesicles and a Novel Form of Communication in the Brain
Basso, M., & Bonetto, V. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00127 · Cited by 161
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Nooshabadi, V. T., Mardpour, S., Yousefi‐Ahmadipour, A., Allahverdi, A., Izadpanah, M., Daneshimehr, F., Ai, J., Banafshe, H. R., & Ebrahimi‐Barough, S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26726 · Cited by 133
Conceição, M., Mendonça, L., Nóbrega, C., Gomes, C., Costa, P., Hirai, H., Moreira, J. N., Lima, M. C., Manjunath, N., & Pereira de Almeida, L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.021 · Cited by 117
Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases
Ciregia, F., Urbani, A., & Palmisano, G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00276 · Cited by 110
Modularized Extracellular Vesicles: The Dawn of Prospective Personalized and Precision Medicine
Tao, S., Guo, S., & Zhang, C. (2018) · Advanced Science · doi:10.1002/advs.201700449 · Cited by 100
Extracellular vesicles in cancer nanomedicine
Tarasov, V. V., Svistunov, A. A., Chubarev, V. N., Dostdar, S. A., Sokolov, A. V., Brzecka, A., Sukocheva, O., Neganova, M. E., Klochkov, S. G., Somasundaram, S. G., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.017 · Cited by 97
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Wang, Q., Cheng, S., Qin, F., Fu, A., & Fu, C. (2021) · RSC Advances · doi:10.1039/d1ra00550b · Cited by 85
Extracellular Vesicles in Modifying the Effects of Ionizing Radiation
Szatmári, T., Hargitai, R., Sáfrány, G., & Lumniczky, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225527 · Cited by 52
Emerging prospects of extracellular vesicles for brain disease theranostics
Wang, R., Wang, X., Zhang, Y., Zhao, H., Cui, J., Li, J., & Di, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.024 · Cited by 48
Fu, C., Xiang, Y., Li, X., & Fu, A. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.029 · Cited by 48
Izadpanah, M., Seddigh, A., Ebrahimi Barough, S., Fazeli, S. A. S., & Ai, J. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1135-x · Cited by 48
Vinod, C., & Jena, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.612692 · Cited by 45
Recent Advances on Extracellular Vesicles in Central Nervous System Diseases
Jin, T., Gu, J., Li, Z., Xu, Z., & Gui, Y. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s288415 · Cited by 44
The Dichotomous Role of Extracellular Vesicles in the Central Nervous System
Graykowski, D. R., Wang, Y.-Z., Upadhyay, A., & Savas, J. N. (2020) · iScience · doi:10.1016/j.isci.2020.101456 · Cited by 39
Glia-derived extracellular vesicles in parkinson’s disease.
Marchetti, B., Leggio, L., L’Episcopo, F., Vivarelli, S., Tirolo, C., Paternò, G., Giachino, C., Caniglia, S., Serapide, M. F., & Iraci, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061941 · Cited by 38
Bortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
Exosome-based drug delivery systems for enhanced neurological therapeutics
Vahab, S. A., V, V. K., & Kumar, V. S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01710-x · Cited by 34
Druzhkova, T. A., & Yakovlev, A. A. (2018) · Neurochemical Journal · doi:10.1134/s1819712418030030 · Cited by 33
Recent Trends in Nanotechnology Toward CNS Diseases
Cardoso, A. M., Guedes, J. R., Cardoso, A. L., Morais, C., Cunha, P., Viegas, A. T., Costa, R., Jurado, A., & Pedroso de Lima, M. C. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.05.002 · Cited by 26
Exosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis
Ojeda-Hernández, D. D., Hernández-Sapiéns, M. A., Reza-Zaldívar, E. E., Canales-Aguirre, A., Matías-Guiu, J. A., Matías-Guiu, J., Mateos-Díaz, J. C., Gómez-Pinedo, U., & Sancho-Bielsa, F. (2022) · Life · doi:10.3390/life12091417 · Cited by 25
Challenges and Promise for Glioblastoma Treatment through Extracellular Vesicle Inquiry
Liguori, G. L. (2024) · Cells · doi:10.3390/cells13040336 · Cited by 24
MicroRNAs change the games in central nervous system pharmacology
Marangon, D., Raffaele, S., Fumagalli, M., & Lecca, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.019 · Cited by 22
Clinical implications of extracellular vesicles in neurodegenerative diseases
Vinaiphat, A., & Sze, S. K. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1657407 · Cited by 20
Jia, Y., Zhuang, X., Zhang, Y., Zhao, M., Chen, N., Li, W., Zhu, F., Guo, C., Li, Y., Wang, Q., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04361-9 · Cited by 17
Ghosh, S., & Ghosh, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878058 · Cited by 13
Metadata
- Authors
- Cooper, J. M., Wiklander, P. B. O., Nordin, J. Z., Al‐Shawi, R., Wood, M. J., Vithlani, M., Schapira, A. H. V., Simons, J. P., El‐Andaloussi, S., & Alvarez‐Erviti, L.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2014-08-11
- Volume
- 29
- Issue
- 12
- Pages
- 1476-1485
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1721689174
- Cited by
- 507
- References
- 24
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.